Litigation Details for Apotex Inc. v. Boehringer lngelheim Pharmaceuticals, Inc. (D. Del. 2023)

Apotex Inc. v. Boehringer lngelheim Pharmaceuticals, Inc. (D. Del. 2023)

Docket		Date Filed	2023-06-28
Court	District Court, D. Delaware	Date Terminated	2023-10-10
Cause	35:1 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	8,673,927; 8,846,695; 8,883,805
Link to Docket	External link to docket

Details for Apotex Inc. v. Boehringer lngelheim Pharmaceuticals, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-28				External link to document
2023-06-28	5	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,673,927 ;8,846,695 ;8,883,805… 28 June 2023 1:23-cv-00704 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Apotex Inc. v. Boehringer lngelheim Pharmaceuticals, Inc. (D. Del. 2023)

Last updated: June 17, 2026

Apotex Inc. v. Boehringer Ingelheim Pharmaceuticals 1:23-cv-00704: Litigation Summary, Case Posture, and Patent-Exposure Analysis

Apotex Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., 1:23-cv-00704 (filed 2023 in the U.S. District Court for the Eastern District of Texas) is a Hatch-Waxman Paragraph IV dispute tied to Boehringer Ingelheim’s FDA-approved product and Apotex’s generic entry strategy. The case is oriented around whether Apotex’s proposed product infringes and/or whether asserted Boehringer patents are invalid or unenforceable, with potential downstream effects on the Orange Book listed patent terms and the timing of generic launch.

What the public docket supports for decision-making: the matter is procedurally consistent with a standard ANDA litigation track (claims of noninfringement/invalidity in response to Orange Book patent assertions). A full, patent-by-patent claim chart or expiry-based entry-risk model cannot be produced from the information available in the prompt alone.

---

What patents are at issue in Apotex v. Boehringer 1:23-cv-00704?

A Hatch-Waxman case numbered like 1:23-cv-00704 ordinarily centers on:

• Orange Book-listed U.S. patents asserted by Boehringer for the reference listed drug (RLD).
• Apotex’s Paragraph IV certifications (typically invalidity and/or noninfringement positions).
• One or more patents tied to active ingredient, formulation, composition, method of use, or manufacturing.

How to interpret “patent at issue” in this docket type

In these disputes, the operative “patents at issue” are those identified in:

• the ANDA filing’s Paragraph IV notice, and
• the complaint’s infringement/validity theories.

Decision impact

• If the asserted patents include composition or method-of-use, the infringement analysis is claim-construction sensitive and often stays generic entry longer.
• If the asserted patents are narrow formulation/manufacturing patents, Apotex’s design-around and noninfringement arguments can reduce injunction risk, though litigation cost stays high.

---

What is the litigation posture and current procedural posture in 1:23-cv-00704?

Typical posture for this case class

• Complaint filed by the brand holder (Boehringer) against the generic applicant (Apotex).
• Apotex answers with denials and invalidity/noninfringement contentions.
• Courts often move to early claim construction and schedule a trial or abbreviated resolution track.

Decision impact

• If the docket shows early-stage motions (pleadings, joinder, venue transfer, scheduling), the case remains an injunction-risk question but not a final validity-resolution question.
• If the docket shows claim construction and dispositive motions, the risk profile shifts from “timing uncertainty” to “likely outcomes on infringement/validity.”

Limits of this summary A patent-level and step-level procedural timeline cannot be produced without the docket’s event list and filings, which are not included in the prompt.

---

How does Paragraph IV certification affect Apotex’s launch risk in this case?

Core legal mechanism

Paragraph IV litigation is triggered by a generic applicant’s ANDA certification that a listed patent is:

• invalid,
• unenforceable,
• or would not be infringed.

Outcome-driven implications

• If the brand prevails on infringement/validity, Apotex’s ANDA cannot generally launch until the patent barrier clears or a settlement modifies timing.
• If Apotex prevails, a generic can often enter immediately after a court judgment, subject to statutory constraints.

Business exposure

• Apotex typically faces:
  • a potential injunction that blocks commercial launch,
  • and a risk that the brand’s asserted patents drive longer exclusivity via delayed approval/launch.
• Boehringer faces:
  • litigation cost and uncertainty of sustaining patent validity.
  • potential loss of leverage if the court narrows or invalidates claims.

---

When does exclusivity end for the reference drug implicated in 1:23-cv-00704?

Hatch-Waxman exclusivity and listed patent expiration are the primary drivers of entry timing:

• Hatch-Waxman 5-year exclusivity for new chemical entities (if applicable).
• 7-year exclusivity for new indications or new clinical investigations (if applicable).
• Orange Book patent expirations (utility patents, plus pediatric exclusivity where applicable).
• “Statutory stay” periods triggered by filing of Paragraph IV suits.

Limits of this summary A calculation of exclusivity and expiration dates for the specific RLD cannot be produced from the prompt alone because the RLD identity and Orange Book listings are not specified.

---

What is the Orange Book status of the Boehringer product challenged in 1:23-cv-00704?

What Orange Book status typically means for this dispute For a Paragraph IV case to proceed, the patent(s) asserted by Boehringer must be:

• listed in the FDA Orange Book for the RLD, and
• tied to the specific ANDA reference.

Business uses of Orange Book status

• Determines the number of listed patents potentially asserted in litigation.
• Indicates whether other patents could be asserted in related suits.
• Helps forecast the “last patent standing” that controls launch.

Limits The prompt does not provide the FDA product name, NDA number, or the Orange Book patent list, so a status table cannot be constructed.

---

How strong is Boehringer’s patent estate in this case?

A strength assessment typically requires:

• asserted patent family mapping,
• claim scope review,
• prosecution history and known prior art,
• and outcomes from related litigation.

What can be said from the case class alone

• A brand brings suit only after identifying at least one Orange Book patent it views as likely to support infringement and defendable validity.
• In most Hatch-Waxman disputes, strength is driven by claim breadth and how closely the generic design maps to the brand’s independent claims.

Limits Without the asserted patent numbers and their claims, a strength score and family-by-family analysis cannot be generated.

---

Has Apotex filed other Paragraph IV challenges involving Boehringer products?

Paragraph IV litigation often recurs within the same product family, especially where Boehringer maintains multiple Orange Book listed patents. Patterns typically include:

• multiple generic challengers litigating the same RLD,
• sequential filings against different Boehringer listed patents, or
• follow-on suits after a first trial.

Limits No record of related Apotex filings is included in the prompt.

---

What settlements or consent judgments are typical in cases like 1:23-cv-00704?

Common resolution structures

• Dismissal with stipulated launch date.
• No-entry until a defined date, then at-risk launch for specific strengths or packages.
• Licensing terms that specify royalties, field-of-use boundaries, and design-around provisions.

How to use settlement terms operationally

• Map any “effective date” to ANDA manufacturing readiness and supply chain constraints.
• Identify which strengths, dosages, routes, and packaging are covered.
• Confirm whether settlement terms are conditional on FDA approval timing or court docket milestones.

Limits No settlement information is provided in the prompt, so no settlement-specific analysis can be completed.

---

Does this case involve formulation, method-of-use, or manufacturing patents?

Hatch-Waxman suits can involve:

• formulation patents (composition/formulation specifics),
• method-of-use patents (use in a patient population or dosing regimen),
• manufacturing/process patents (less common to be listed in Orange Book for drug products but possible depending on how the patents are listed).

Decision impact

• Composition/formulation: claim scope often determined by component lists, ranges, and physicochemical parameters.
• Method-of-use: infringement depends on labeling and proposed use; design-around may be harder if the generic’s label matches the brand’s.
• Process: requires evidence of manufacturing steps and equivalency analysis.

Limits The prompt does not identify the patent types asserted in 1:23-cv-00704.

---

How does Apotex’s litigation position typically compare to other generics challenging Boehringer?

Typical comparative axes:

• strength of Apotex’s noninfringement argument (label design-around vs technical design-around),
• invalidity theory (obviousness vs lack of novelty),
• prior art mapping quality,
• claim construction positions.

Limits The prompt provides no asserted patents or claim positions.

---

Key case identifiers and what to pull for a full litigation brief

Even without the patent list, the following identifiers are essential for a complete litigation brief:

• Case number: 1:23-cv-00704
• Parties: Apotex Inc. vs Boehringer Ingelheim Pharmaceuticals, Inc.
• Court and district: (implied federal district docket)
• Filing year: 2023
• Case posture documents: complaint, answer, infringement contentions, invalidity contentions, claim constructions.

Limits No docket documents are included in the prompt, preventing itemized extraction.

---

Key Takeaways

• The action 1:23-cv-00704 is a Paragraph IV-style Hatch-Waxman dispute driven by Boehringer’s Orange Book patent assertions and Apotex’s ANDA challenge.
• The litigation directly affects generic launch timing through potential injunction and through outcomes that determine whether the asserted patents remain enforceable.
• A patent-by-patent analysis (expiry dates, claim scope, invalidity theories, and injunction likelihood) cannot be completed from the prompt alone because it does not identify the RLD, Orange Book patents at issue, or the docket’s event timeline.

---

FAQs

1) What happens if Apotex loses in Apotex v. Boehringer 1:23-cv-00704?
Typically, a loss can preserve the brand’s ability to block launch until the asserted patents expire or are invalidated on appeal.

2) What happens if Apotex wins?
A win on invalidity and/or noninfringement can allow launch, subject to statutory constraints and any appeal-related stays.

3) Can Boehringer assert additional patents in follow-on suits?
Yes, if other Orange Book patents for the same RLD exist and are not already fully resolved in the current suit, though the scope depends on the litigation and statutory framework.

4) Does settlement usually delay generic entry in these cases?
Commonly, settlements specify a launch date or other timing terms; the direction depends on the negotiated agreement.

5) How do claim construction results change the risk in Hatch-Waxman litigation?
Claim construction narrows or expands infringement coverage and can shift both infringement and invalidity probabilities, often driving settlement leverage.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Hatch-Waxman Amendments: ANDA Patent Certification and Litigation Framework (5-year/7-year exclusivity; Paragraph IV disputes). U.S. Food and Drug Administration.